Axsome Therapeutics (AXSM) Debt to Equity (2016 - 2026)

Axsome Therapeutics' Debt to Equity history runs 11 years deep, the most recent figure standing at $2.36 for Q1 2026.

• In Q1 2026, Debt to Equity fell 33.82% year-over-year to $2.36; the TTM figure through Mar 2026 stood at $2.36 (down 33.82% YoY), while the FY2025 annual figure was $1.45, down 54.35% from the prior year.
• Debt to Equity came in at $2.36 for Q1 2026 at Axsome Therapeutics, up from $1.45 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $6.54 in Q2 2022 to a low of $0.64 in Q3 2022.
• A 5-year average of $2.06 and a median of $1.73 in 2025 frame the typical range for Debt to Equity.
• Across the five-year window, Debt to Equity soared 855.82% in 2022 and plunged 89.96% in 2023, its largest moves.
• Axsome Therapeutics' Debt to Equity stood at $0.91 in 2022, then climbed by 5.66% to $0.97 in 2023, then jumped by 228.12% to $3.17 in 2024, then sank by 54.35% to $1.45 in 2025, then surged by 63.32% to $2.36 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $2.36, $1.45, and $1.73 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison